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In recent years, Fanconi anemia (FA) has been the subject of intense investigations, primarily in the DNA repair research
ﬁeld. Many discoveries have led to the notion of a canonical pathway, termed the FA pathway, where all FA proteins function
sequentially in diﬀerent protein complexes to repair DNA cross-link damages. Although a detailed architecture of this DNA cross-
linkrepairpathwayisemerging,thequestionofhowadefectiveDNAcross-linkrepairprocesstranslatesintothediseasephenotype
is unresolved. Other areas of research including oxidative metabolism, cell cycle progression, apoptosis, and transcriptional
regulation have been studied in the context of FA, and some of these areas were investigated before the fervent enthusiasm in
the DNA repair ﬁeld. These other molecular mechanisms may also play an important role in the pathogenesis of this disease. In
addition, several FA-interacting proteins have been identiﬁed with roles in these “other” nonrepair molecular functions. Thus, the
goal of this paper is to revisit old ideas and to discuss protein-protein interactions related to other FA-related molecular functions
to try to give the reader a wider perspective of the FA molecular puzzle.
1.Th eF AClinicalPh e no type
Fanconi anemia (FA) is a complex disease that is considered
a congenital form of aplastic anemia. The genetic mode of
transmission is both autosomal and X-linked, and a growing
numberofidentiﬁedgenesaredistributedamongthevarious
chromosomes. The common clinical manifestation in most
patients with FA, which may occur in all FA patients
eventually, is life-threatening bone marrow failure (BMF)
[1, 2]. FA is also associated with diverse birth defects and
a predisposition to malignancies. FA-associated congenital
malformations can aﬀect many organ systems including the
central nervous system, the gastrointestinal system, and the
skeletal system [3–8]. Other ﬁndings in patients with FA
include short stature, skin pigmentation abnormalities, and
small facial features. In addition, more than 70% of patients
with FA show endocrine dysfunctions including deﬁciencies
in growth hormone and thyroid hormone as well as diabetes
[9, 10]. All of these disease manifestations suggest a role
for FA genes in mechanisms that bear on hematopoiesis,
development, and neoplasia.
2.The FAMolecularPathway
Patients with FA are classiﬁed into complementation groups
( t od a t e1 4g r o u p sf r o mAt oPh a v eb e e ni d e n t i ﬁ e d ) ,a n da l l
of these groups correspond to one of the following cloned
genes: FANCA, FANCB, FANCC, FANCD1/BRCA2,
FANCD2, FANCE, FANCF, FANCG, FANCI, FANCJ/BRIP1/
BACH1, FANCL/PHF9, FANCM/HEF, FANCN/PALB2, and
FANCP/SLX4 [11–27]. Approximately 85% of FA patients
have a defective FANCA, FANCC or FANCG gene, while the
other genes account for less than 5% of the mutations found
in FA patients. To date, some patients still remain unassigned
indicating the possibility of novel FA genes [28]. Mutations
in the RAD51C gene (provisionally termed FANCO)h a v e
been associated with a FA-like disorder, suggesting that this
gene may represent yet another FA gene [29, 30]. Patients2 Anemia
with mutations in one of the 15 FA and FA-like genes present
clinical FA aspects to various degrees but show a common
cellular phenotype: hypersensitivity to DNA cross-linking
agents such as mitomycin C (MMC), diepoxybutane, and
cisplatin [28, 31]. When exposed to those agents, cells from
FA patients show an abnormally prolonged cell cycle arrest
in the G2/M phase, increased chromosomal aberrations,
and reduced survival. These cellular features deﬁne FA, and
presumably, all FA proteins cooperate in a pathway, termed
the FA pathway, to maintain chromosome integrity.
In the canonical FA pathway, FA proteins are subdivided
into three complexes based on protein-protein interaction
studies. The ﬁrst complex, known as the core complex or
complex I, is composed of seven FA proteins, including
FANCA, FANCB, FANCC, FANCE, FANCF, FANCG, and
FANCL [22, 27, 32–40]. The FANCM protein was also
considered part of this core complex; however, further
analysis revealed confounding results in FANCM-mutated
cells [41]. Other proteins found in association with the core
complex include Fanconi anemia-associated protein 24
(FAAP24), FAAP100, FANCM-associated histone fold pro-
tein 1 (MHF1), MHF2, and hairy enhancer of split 1 (HES1)
[42–44]. All of these associated proteins are required for
eﬃcient FA pathway activation, but disease-causing muta-
tions have yet to be found. Following DNA cross-link
damage, the core complex associates with the FANCM-
FAAP24 heterodimer on the chromatin [27, 39, 45, 46]a n d
monoubiquitinates, through the activity of the FANCL E3
ubiquitinligase,thecomplexII(orIDcomplex)components
FANCD2 and FANCI [22, 47–50]. This ubiquitin tag alters
the cellular distribution of complex II and promotes its
association with the FA pathway complex III components
FANCD1, FANCJ, FANCN and FANCP, and the FA-like
disorder protein RAD51C [29, 30]. Complex III, similar to
FANCM, is dispensable for the monoubiquitination of ID
complex components, supporting the role of FA proteins
in a linear (or canonical) response pathway. The deubiqui-
tination of FANCD2 and FANCI by the UAF1/USP1 deu-
biquitinating enzyme complex appears to be required for the
completion of the repair process [50–52].
3.FAProteinCellularLocalization
One intriguing aspect of the FA molecular pathway is the
cellular distribution of FA proteins. Although the well-
characterized function of this pathway in DNA crosslink
damage occurs in the nucleus, FA core complex proteins can
be found in diﬀerent cellular compartments in addition to
the nucleus.
The ﬁrst identiﬁed FA protein, FANCC, is principally
found in the cytoplasm [53–56]. It was ﬁrst reported that
FANCC function in DNA cross-links resistance required
its cytoplasmic location and that enforced nuclear FANCC
expression abolished its ability to correct FA-C cells [55, 57].
It was later found that FANCC is partially localized to the
nucleus, and this FANCC nuclear localization is critical for
the function of the FA core complex in DNA crosslink res-
ponses [56, 58]. These conﬂicting results may suggest that
FANCC is required in both cellular compartments, and that
regulation of its protein level in each cellular compartment
is important for its function. The molecular chaperone,
glucose-related protein 94 (GRP94) involved in protein
qualitycontrol,proteinfolding,andERstressresponses[59],
directly binds FANCC and regulates its intracellular levels
[60]. Reducing the levels of GRP94 through the use of a
speciﬁc ribozyme aﬀects FANCC stability and renders cells
hypersensitive to MMC suggesting a possible mechanism of
FANCC quality control and subsequent cellular localization.
FANCA cellular localization has been extensively studied
[32, 36, 37, 61–63]. FANCA possesses a bipartite nuclear
localization signal (NLS) domain that is required for its
nuclear shuttling [64] and contains ﬁve nuclear export signal
NES domains involved in chromosome region maintenance
1 (CRM1/exportin 1)-dependent nuclear export [65]. It has
been proposed that the interaction of FANCA with the
sorting nexin 5 protein (SNX5) may be involved in its
subcellular traﬃcking [66]. Other studies have reported that
FA core complex proteins could be found in the cytoplasm,
in an unbound form, but also in a 600kDa complex
composed of at least four FA core complex proteins (i.e.,
FANCA, FANCC, FANCF, and FANCG) [57, 61, 67, 68].
Other studies have suggested the formation of diﬀerent
cytoplasmic subcomplexes, including FANCA/FANCG [36,
38], FANCB/FANCL [23], and FANCC/FANCE [33, 69–71].
It has been suggested that these subcomplexes are probably
translocated to the nucleus independently before association
into a core complex through FANCF, which acts as a linker
protein [33, 72].
Because the nuclear presence of both FANCC and
FANCE depends on each other, an interdependence between
FAproteinshasbeenproposed.Indeed,studiesonFAmutant
cell lines have shown that the core complex fails to form
if one protein is absent or mutated [33]. Studies of syn-
chronized cells have shown that FA proteins shuttle between
the nucleus and the cytoplasm during the cell cycle. Early
in the G1 phase, FA core complex proteins are localized to
the cytoplasm, at the G1-S border, they are loaded onto
chromatin, and throughout mitosis they migrate to the
nuclear periphery to become completely excluded from the
condensed chromosomes [67, 73, 74]. The exclusion of
FA proteins from condensed chromosomes occurs in the
absence of DNA damage, whereas treatment with MMC
results in an increased binding of core complex proteins to
chromatin [67, 73, 75]. Considering these results, it is not
inconceivable to surmise that the cytoplasmic forms of FA
proteins or FA subcomplexes are likely to be critical for cell
signaling events in normative conditions.
4. PosttranslationalModiﬁcationofFAProteins
FA proteins undergo multiple posttranslational modiﬁca-
tions, including monoubiquitination, phosphorylation and
proteolytic processing. The most widely studied modiﬁca-
tion is the monoubiquitination of FANCD2 and FANCI.
Although only two of the ﬁfteen FA proteins are monoubiq-
uitinated, several FA proteins, including FANCA, FANCE,Anemia 3
FANCG, FANCD2, FANCI, and FANCM, are phosphoryl-
ated, and two FA proteins are regulated through a caspase-
mediated proteolytic process. These data suggest that post-
translationalmodiﬁcationsplayanimportantroleinFApro-
teins activity. In this section, we will only discuss FA protein
modiﬁcations other than the ubiquitination of FANCD2 and
FANCI because it has been extensively discussed [47, 76, 77].
The FANCA protein was the ﬁrst FA protein shown to be
phosphorylated [58, 63, 78]. The FANCA phosphorylation
site was ﬁrst thought to be located at S1149 [79], which
harbors an AKT kinase consensus sequence; however, the
FANCA S1149A mutant was shown to be more eﬃciently
phosphorylated than wildtype FANCA. The FANCA phos-
phorylation site was later identiﬁed by mass spectrometry
as serine 1449 [80]. The phosphorylation of FANCA at
S1449 is functionally important because it was found to be
defective in lymphoblasts from several patients with FA, and
FANCA S1449A failed to fully rescue FA-A mutant cells. A
novel wortmannin-sensitive protein kinase termed FANCA-
PK was ﬁrst suggested as the kinase responsible for FANCA
phosphorylation [81]; however, the true kinase that phos-
phorylates FANCA in response to DNA damage was later
identiﬁed as ATR [80]. FANCA was also shown to associate
with the IKK signalosome through direct interaction with
IKK2, the IκB Kinase-2 [82]. Although this kinase aﬀected
the phosphorylation state of several FANCA-associated
proteins, no clear, direct phosphorylation of FANCA by
IKK2 has been reported. Diﬀerent groups have reported that
FANCG is also phosphorylated. FANCG phosphorylation
occurs at serines 7, 383, and 387, with the two latter
sites being cell cycle-dependent and actively phosphorylated
during mitosis [83–85]. The exclusion of FA proteins from
chromosomes during mitosis appears to coincide with phos-
phorylated FANCG. All the FANCG phosphorylation sites
are functionally important because mutant forms of these
FANCGserineresiduescompromiseditsabilitytorescueFA-
G mutant cells. The FANCC-interacting protein kinase cdc2
[86] was shown to be required for the phosphorylation of
at least the S387 FANCG residue. The kinases responsible
for the phosphorylation of the other FANCG target sites are
unknown.
The FANCD2 protein undergoes two diﬀerent posttrans-
lational modiﬁcations. In addition to monoubiquitination
onlysine561,FANCD2isphosphorylatedonseveralresidues
by diﬀerent kinases depending on the cellular signal. In
response to various DNA damaging agents, including ultra-
violet light, MMC, hydroxyurea, and ionizing radiation,
FANCD2 is phosphorylated on T691 and S717 followed
by S222 in an ATM/ATR-dependent mechanism [87, 88].
S222 phosphorylation triggers the activation of an intra-
S-phase checkpoint response. In addition, the FANCD2-
T691A/S717A double mutant does not complement the
MMC sensitivity in FA-D2 cells, suggesting that this post-
translational modiﬁcation is required for FANCD2 func-
tion in the DNA damage response. Other ATM-dependent
FANCD2 phosphorylation sites have been described and
have been shown to be functional in in vitro assays, including
S1401,S1404,andS1418,andonlyS1401hasbeenconﬁrmed
in vivo. S331 of FANCD2 has been shown to be phosphory-
lated by the checkpoint kinase 1 (CHK1) and is essential for
MMC resistance [89]. Although FANCD2 phosphorylation
is independent of other posttranslational modiﬁcations, it
promotes or enhances the monoubiquitination process. For
instance, ATR-mediated phosphorylation of FANCD2 is
essential for its monoubiquitination in response to DNA
damage as shown by absence of FANCD2 monoubiquiti-
nation in ATR-deﬁcient cells and cells from patients with
Seckel syndrome, a disease resembling FA [90]. FANCI was
identiﬁed in the search for ATR-inducible phosphorylated
proteins in response to ionizing radiation [50]. Three phos-
phorylation sites were detected in the human FANCI protein
(S730,T952,andS1121),andtwoothersitesweredetectedin
themouseprotein(S555andT558).FANCIphosphorylation
is essential for the FA pathway activation following DNA
damage as measured by FANCD2 monoubiquitination [91].
FANCE and FANCM phosphorylation has also been
studied in the context of induced DNA damage. In response
toDNAdamage,CHK1wasshowntophosphorylateFANCE
on two residues, notably T346 and S374 [92]. FANCE
phosphorylation is required for MMC resistance but is dis-
pensable for FA pathway activation as measured by FANCD2
monoubiquitination. The CHK1-induced phosphorylation
of FANCE promotes its assembly with FANCD2 into nuclear
foci and promotes its degradation, serving as a potential
negative regulatory mechanism of the FA pathway. FANCM
is a phosphoprotein that contains multiple predicted ATR
phosphorylation sites and becomes hyperphosphorylated in
response to DNA damage and during mitosis [27, 93].
FANCM phosphorylation occurs independently of the FA
core complex activation leading to the monoubiquitination
of the ID complex.
Finally, another posttranslational modiﬁcation found in
FANCC is caspase-mediated proteolytic processing [94].
Similar to many proteins involved in signaling mechanisms,
FANCC is cleaved by a caspase during apoptosis. This pro-
teolytic modiﬁcation of FANCC is not required for its
function in DNA repair or DNA damage signaling, but the
cleavage of FANCC inhibits its suppressor of apoptosis func-
tion. Recently, a second FA protein, FANCD2 was shown to
be regulated by a caspase-mediated proteolytic processing
in response to DNA crosslink damage and the non-DNA
damaging agent TNF-α [95]. Both the TNF-α and DNA
crosslink-mediated disappearance of FANCD2 was blocked
by caspase inhibitors but not by proteasome inhibitors,
suggesting that FANCD2 is regulated through a caspase-
dependent mechanism in response to cellular stress.
5.FAProteinsPartnerswithRoles in
OxidativeMetabolism
The abnormal sensitivity of FA cells to reactive oxygen
species (ROS) was ﬁrst suggested in 1977 by Nordenson [96]
who showed reduced chromosomal breaks in FA lymph-
ocytes cultured in the presence of superoxide dismutase,
catalase, or both enzymes. The role of oxygen on chro-
mosomal instability in FA mutant cells was conﬁrmed by4 Anemia
Table 1: List of FA protein partners.
Functional class Speciﬁc function Protein name Interacts with References
Transcription
Transcriptional repressor FAZF FANCC [112, 147]
HES1 FANCA, F, G, L [44]
Stress-induced chaperone Hsp70 FANCC [112, 140]
GRP94 FANCC [60, 112]
Chromatin modiﬁer BRG1 FANCA [112, 154]
Cell cycle Serine/threonine kinase cdc2 FANCC [86, 112]
Cell signaling
Cytokine response STAT1 FANCC [133]
IKK2 FANCA [79, 82, 112]
Secondary modiﬁcation Akt kinase FANCA [79, 112]
Oxidative metabolism
Electron transfer RED FANCC [112, 114]
Cytosolic Detoxifying enzyme GSTP1 FANCC [112, 113]
Metabolism of xenobiotics CYP2E1 FANCG [112, 115]
Antioxidant enzyme PRDX3 FANCG [68]
Transporter Intracellular traﬃcking SNX5 FANCA [66, 112]
Joenje et al. in 1981; they showed attenuated chromosomal
aberrations at low oxygen tension (5%) but aggravated chro-
mosomal aberrations at high concentrations of oxygen [97].
Subsequently, several reports indicated that FA cells were
hypersensitive to oxygen radicals showing reduced growth
and blockage in the G2 phase of the cell cycle [98–101].
Increased ROS in FA leucocytes has also been reported [99].
In addition, the overexpression of detoxifying enzymes, the
inhibition of enzymes involved in oxidation or the use of
antioxidants in FA cells reduced the rate of spontaneous
chromosomal breakage and abolished the DNA damaging
eﬀectsofMMC[98,102–106].Otherstudieshaveestablished
a link between an altered redox state and reduced prolifera-
tion, reduced growth, and altered cytokine responses in FA
cellsincluding hematopoietic progenitors[107–110].Studies
from FancC/Sod1 double mutant mice exhibiting defects in
hematopoiesis including bone marrow hypocellularity and
cytopenia, which is reminiscent of phenotypes observed in
patients with FA, suggest that an abnormal redox state con-
tribute to BMF in FA [111].
Together, these data indicate that FA proteins may be
involvedinresponsestoendogenousoxidativestressorinthe
regulation of the cell redox state. This hypothesis is further
supported by studies showing interactions between FA
proteins and proteins involved in oxygen metabolism [112].
For instance, FANCC has protein partners with roles in
redox metabolisms, including glutathione S-transferase π I
(GSTπI) and NADPH cytochrome-P450 reductase (RED)
[113, 114], whereas FANCG interacts with cytochrome
P450 2E1 (CYP2E1) and the mitochondrial peroxiredoxin-
3 (PRDX3) [68, 112, 115]. Through these interactions, FA
proteins were shown to attenuate the redox activation of
xenobiotics and to prevent apoptosis. Consequently, in FA
mutant cells, a loss of interaction between FA proteins and
these molecular antioxidants leads to an aberrant redox
metabolism that translates into ROS-mediated DNA damage
and cell death (see Table 1).
6.FAProteinsPartnerswithRoles in
CytokineSignalingandApoptosis
It is well established that FA mutant cells are prone to
apoptosis. The FA literature is rich in reports pertaining to
FA mutant cells (human bone-marrow-derived cells, lymph-
ocytes, ﬁbroblasts, and mouse embryonic ﬁbroblasts) that
show increased apoptosis or reduced cell growth in response
to various agents including ROS inducers, DNA damag-
ing agents, growth factor withdrawal, and cytokines. It is
clear from many studies of patient-derived cells and cells
from FA mouse models that FA proteins are involved in
pathways that regulate cell survival or cell death [116–121].
For instance, two FA proteins, FANCC and FANCD2, are
caspase targets [94, 95], and FANCC overexpression or the
inhibitionofitscaspase-mediatedcleavagepreventsordelays
apoptosis, even in wildtype cells supporting the idea of a
cell survival function of the FA proteins [94, 119, 122].
The role of FANCC in cell survival has been linked to
oxidative metabolism as described above but it may also
be linked to cytokine-mediated cellular responses because
many cytokine-mediated signaling events lead to apoptosis.
It has been suggested that abnormal cytokine regulation may
account for the progressive BMF observed in patients with
FA because TNF-α overproduction and underproduction of
Il-6 have been detected in the sera of patients with FA
[123–125]. FA-C mutant cells and FancC−/− progenitor and
stem cells are hypersensitive to the inhibitory cytokines
including TNF-α and IFN-γ, and show suppressed growth
and increased apoptosis at doses that do not aﬀect normal
cells [116, 122, 126, 127]. In addition, the continuous
injection of low IFN-γ doses in vivo leads to BMF in FAAnemia 5
mice [128, 129], whereas TNF-α leads to clonal evolution
and leukemia in this FA mouse model [130]. In support of
these altered cytokine responses in FA cells, the cytokine-
response genes myxovirus A (MxA), IFN response factor
1( IRF1), p21CIP/WAF, and IFN-stimulated gene factor 3
(ISGF3γ) were highly expressed in FA mutant cells with-
out exogenous cytokine stimulation, while corrected cells
suppressed this overproduction and restored their MMC
resistance [116, 131, 132]. These data suggest that FA pro-
teins, or at least FANCC, function to modulate a cytokine-
mediated signal. Indeed, FANCC was shown to directly
interact with signal transducer and activator of transcription
1 (STAT1), which is an IFN signal transducer [133]. FANCC
functions as a control factor for STAT1 docking at the
IFN-γR complex and subsequent activation of the IFN
type II signaling cascade [133]. Thus, the STAT1 activation
defect observed in FA-C cells results in an altered nuclear
STAT1-DNA complex, which diminishes the expression of
IRF1. The STAT1-FANCC interaction is also induced by
other cytokines, including IFN-α, granulocyte-macrophage
colony-stimulating factor (GM-CSF), and stem cell factor,
whereas mutant FANCC does not associate with STAT1 in
cells stimulated with these factors. FANCC seems to regulate
IFNγ-inducible genes (e.g., IRF1, p21WAF, and ISGF3γ)
independently of STAT1 binding. An altered response to type
I IFN was also observed in FANCC mutant and FancC−/−
cells, as shown by the reduced phosphorylation of the Janus
kinases, Jak1 and Tyk2, and the subsequently diminished
phosphorylation of STAT1, STAT3, and STAT5 [134]. This
altered Tyk2 response translates into reduced numbers of
CD4-positive cells in FancC−/− mice. Because Tyk2 plays a
role in the diﬀerentiation and maintenance of T helper cells,
failure of FANCC to normally activate Jak/STAT signaling
may result in impaired immune cell diﬀerentiation and
immune defects, as reported in patients with FA [135–139].
FANCC has been shown to physically interact with
Hsp70[140].Thisinteractionappearstoberequiredforpro-
tectionagainstTNF-α andIFN-γ-inducedapoptosisbecause
reduced Hsp70 expression sensitizes normal cells to these
cytokines but does not further augment the hypersensitivity
to apoptosis in FA-C cells. Because Hsp70 is known to
suppress the IFN-inducible double-stranded RNA (dsRNA)-
dependent protein kinase (PKR) activation [141]a n dF A - C
c e l l sh a v ec o n s t i t u t i v e l ya c t i v a t e dP K R[ 142], FANCC was
shown to inhibit the kinase activity of PKR through physical
interaction with Hsp70 [143]. Although this activity is inde-
pendent of a functional FA complex, the FA core complex
protein FANCA was found to interact with IKK2 (or IKKβ)
a kinase and a component of the IKK signalosome [82].
The IKK signalosome is a critical mediator of the cellular
response to stressors such as dsRNA and cytokines [144,
145]. Deletion of IKK2 has been shown to aﬀect the devel-
opment of CD4-positive cells [146]. Because FancC−/− mice
have reduced numbers of CD4+ cells and two FA proteins
have partners that participate in cytokine-activated signaling
cascades aﬀecting the development of these lymphocytes, we
can speculate that FA proteins may act as converging key
molecules.
7.FAProteinPartnerswith
Roles in Transcription
Another FA protein role less considered is the regulation of
transcription. Several FA proteins have interacting partners
directly involved in transcriptional regulation. The ﬁrst FA
protein partner identiﬁed that acts in transcription is FAZF
(FA Zinc Finger) [147]. FAZF, also known as RoG (for
repressor of GATA) [148], PLZP (for PLZF-like zinc ﬁnger
protein) [149] and TZFP (for testis zinc ﬁnger) [150], is
a transcriptional repressor that belongs to the BTB/POZ
family of proteins and is similar to the PLZF protein [147].
This family of transcriptional repressors was shown to be
important for several developmental processes including
tissueproliferationanddiﬀerentiationandtumorformation.
FAZF was identiﬁed in a yeast 2-hybrid screen with FANCC.
FAZF was shown to be highly expressed in CD34-positive
progenitor cells; it further increased during proliferation of
these cells and decreased during their terminal diﬀerentia-
tion [151]. FAZF acts as a negative regulator of transcription.
Because a disease-causing mutation in FANCC interferes
with FAZF binding [147], and FancC−/− hematopoietic
stem/progenitor cells show increased cycling and aberrant
cell cycle control [152], a plausible hypothesis is that the
FANCC-FAZF interaction in hematopoietic stem/progenitor
cells leads to the repression of critical target genes required
for growth suppression.
A second transcriptional repressor identiﬁed as a FA-
binding protein is the hairy enhancer of split 1 (HES1) [44].
HES1 is a member of a highly conserved family of hairy-
related basic helix-loop-helix (bHLH)-type transcriptional
repressors. HES1 was shown to interact directly with several
components of the FA core complex. The FA core complex
was shown to contribute to the transcriptional regulation
of HES1-responsive genes, both positively (HES1) and neg-
atively (cyclin-dependent kinase inhibitor p21cip1/waf1). Two
mechanisms of regulation by FA proteins have been pro-
posed. The ﬁrst proposed mechanisms is that by interacting
with HES1, FA core complex proteins antagonize HES1-
mediated transcriptional repression by interfering with the
assembly of the HES1/transducing-like-enhancer of split
(TLE) corepressor complex at the HES1 promoter [153]. The
secondproposedmechanisminvolvesanindirectmechanism
where the binding of FA proteins with HES1 inﬂuences
HES1 aﬃnity or its speciﬁcity for promoters, such as that of
p21cip1/waf1.
The brahma-related gene 1 protein (BRG1) has also been
identiﬁed as a FA-binding partner through a yeast 2-hybrid
screen [154]. BRG1 is the central catalytic subunit of the
SWI/SNF family of ATP-dependent chromatin remodeling
complexes [155]. BRG1 is a major coregulator of transcrip-
tion, both in activation and repression, through chromatin
modulation. Although the FANCA-BRG1 interaction has
been shown in cells, the functional impact of this interaction
remains unclear.
In view of these FA protein partners with roles in trans-
criptional regulation and the fact that the FA core complex
possesses E3 ubiquitin ligase activity, it is possible that
FA proteins act as transcriptional coregulators through6 Anemia
Apoptosis
oxidative damage
Red
GSTP1
HSP70 
PKR 
C
G
Cyp2E1
PRDX3
NF-KB
Transcription 
deregulation
Hes1
differentiation
Development
Fanconi anemia
Proinﬂammation
NF-KB
Immunological defect
FA pathway
D2 I G
F
A
E C
L
B M
G
F A
A
IKK2
E C
L
B M
D2 I
Ub Ub
D1
N J
Neoplasia
DNA repair
Bone marrow failure
↓Th
↓
↓
↓
↓
Tyk2
↑
↑
↑
↑
↑
↑
STAT1
TNF-α
Figure 1: Putative roles of FA proteins through their interacting partners. The involvement of FA proteins with their protein partners in
the diﬀerent molecular mechanisms that lead to regulation of transcription, cell cycle regulation, ROS detoxiﬁcation, DNA repair, and cell
survival. Loss of protein interactions between FA proteins and their partners through disease causing mutations in a FA gene could lead to a
defective molecular function resulting in an array of phenotypes including BMF and congenital malformations.
the posttranslational modiﬁcation of these transcriptional
regulators.
8. Conclusion
Since the discovery of FANCC, the ﬁrst identiﬁed FA gene
in 1992 [15], there have been signiﬁcant advances in the
FA molecular biology ﬁeld. These advances mostly include
characterization of the canonical FA pathway, which is
activated in response to DNA crosslink damage. It is clear
that FA proteins are required for DNA crosslink repair;
however, the question of how a defective FA protein leads
to BMF, and developmental abnormalities remains elusive.
It is obvious that absence of a functional FA protein aﬀects
many cellular and molecular functions and leads to an array
of cellular phenotypes (see Figure 1). A perplexing question
is whether FA proteins interactions with their nonrepair
partners act only as modiﬁers of the clinical manifestation of
FA. Once we reconcile all the notions related to FA proteins
role in these various cellular and molecular activities, we
may then obtain a clearer picture of the complexities of this
molecular puzzle.
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